Alkermes To Spin Out Oncology Business, Says Inflation Reduction Act Boosts Its Value
Company Raised CNS Product Revenue Guidance
After a year of strong commercial performance for Lybalvi and with IL-2 drug nemvaleukin in registration-enabling studies, Alkermes is ready to separate its neuroscience and oncology businesses.
